SBTX vs. BVXP, CIR, 4BB, HVO, AVCT, TILS, VSN, SCLP, MPH, and ORPH
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Bioventix (BVXP), Circassia Group (CIR), 4basebio (4BB), hVIVO (HVO), Avacta Group (AVCT), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics vs.
SkinBioTherapeutics (LON:SBTX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
Bioventix has a net margin of 59.51% compared to SkinBioTherapeutics' net margin of -237.95%. Bioventix's return on equity of 69.09% beat SkinBioTherapeutics' return on equity.
Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
SkinBioTherapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Bioventix has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.
Bioventix received 45 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 52.87% of users gave Bioventix an outperform vote.
16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 62.3% of Bioventix shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 8.0% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, SkinBioTherapeutics and SkinBioTherapeutics both had 1 articles in the media. Bioventix's average media sentiment score of 0.55 beat SkinBioTherapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the news media.
Summary
Bioventix beats SkinBioTherapeutics on 10 of the 14 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
This page (LON:SBTX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy SBTX Stock Free SBTX Stock Alerts